<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gordon AC</submitter><funding>Robert H Lurie Comprehensive Cancer Center Pathology Core Facility</funding><funding>ACG Medical Scientist Training Program</funding><funding>Investigator Initiated Study</funding><funding>SIR Foundation Allied Scientist Grant</funding><funding>Department of Radiology of the Feinberg School of Medicine</funding><funding>NCI NIH HHS</funding><funding>RSNA Foundation Research Scholar Grant</funding><funding>NIH</funding><funding>Northwestern University Mouse Histology and Phenotyping Laboratory which is supported by NCI</funding><funding>NIGMS NIH HHS</funding><pagination>849-858</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7719607</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>28(6)</volume><pubmed_abstract>&lt;h4>Rationale and objectives&lt;/h4>To use a rapid gas-challenge blood oxygen-level dependent magnetic resonance imaging exam to evaluate changes in tumor hypoxia after &lt;sup>90&lt;/sup>Y radioembolization (Y90) in the VX2 rabbit model.&lt;h4>Materials and methods&lt;/h4>White New Zealand rabbits (n = 11) provided a Y90 group (n = 6 rabbits) and untreated control group (n = 5 rabbits). R2* maps were generated with gas-challenges (O&lt;sub>2&lt;/sub>/room air) at baseline, 1 week, and 2 weeks post-Y90. Laboratory toxicity was evaluated at baseline, 24 hours, 72 hours, 1 hours, and 2 weeks. Histology was used to evaluate tumor necrosis on hematoxylin and eosin and immunofluorescence imaging was used to assess microvessel density (CD31) and proliferative index (Ki67).&lt;h4>Results&lt;/h4>At baseline, median tumor vo</pubmed_abstract><journal>Academic radiology</journal><pubmed_title>Yttrium-90 Radioembolization and Tumor Hypoxia: Gas-challenge BOLD Imaging in the VX2 Rabbit Model of Hepatocellular Carcinoma.</pubmed_title><pmcid>PMC7719607</pmcid><funding_grant_id>CA126809</funding_grant_id><funding_grant_id>T32 GM008152</funding_grant_id><funding_grant_id>R01 CA126809</funding_grant_id><funding_grant_id>P30 CA060553</funding_grant_id><funding_grant_id>R25 CA132822</funding_grant_id><funding_grant_id>5R25 CA 132822-03</funding_grant_id><funding_grant_id>T32GM008152</funding_grant_id><funding_grant_id>R01 CA209886</funding_grant_id><funding_grant_id>P30-CA060553</funding_grant_id><funding_grant_id>U54 CA199091</funding_grant_id><funding_grant_id>R01 CA241532</funding_grant_id><pubmed_authors>Lewandowski RJ</pubmed_authors><pubmed_authors>Gates VL</pubmed_authors><pubmed_authors>White SB</pubmed_authors><pubmed_authors>Omary RA</pubmed_authors><pubmed_authors>Li W</pubmed_authors><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Salem R</pubmed_authors><pubmed_authors>Procissi D</pubmed_authors><pubmed_authors>Zhang Z</pubmed_authors><pubmed_authors>Huang X</pubmed_authors><pubmed_authors>Harris KR</pubmed_authors><pubmed_authors>Larson AC</pubmed_authors><pubmed_authors>Lyu T</pubmed_authors><pubmed_authors>Gordon AC</pubmed_authors></additional><is_claimable>false</is_claimable><name>Yttrium-90 Radioembolization and Tumor Hypoxia: Gas-challenge BOLD Imaging in the VX2 Rabbit Model of Hepatocellular Carcinoma.</name><description>&lt;h4>Rationale and objectives&lt;/h4>To use a rapid gas-challenge blood oxygen-level dependent magnetic resonance imaging exam to evaluate changes in tumor hypoxia after &lt;sup>90&lt;/sup>Y radioembolization (Y90) in the VX2 rabbit model.&lt;h4>Materials and methods&lt;/h4>White New Zealand rabbits (n = 11) provided a Y90 group (n = 6 rabbits) and untreated control group (n = 5 rabbits). R2* maps were generated with gas-challenges (O&lt;sub>2&lt;/sub>/room air) at baseline, 1 week, and 2 weeks post-Y90. Laboratory toxicity was evaluated at baseline, 24 hours, 72 hours, 1 hours, and 2 weeks. Histology was used to evaluate tumor necrosis on hematoxylin and eosin and immunofluorescence imaging was used to assess microvessel density (CD31) and proliferative index (Ki67).&lt;h4>Results&lt;/h4>At baseline, median tumor vo</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jun</publication><modification>2025-04-21T21:24:30.999Z</modification><creation>2025-04-05T18:22:16.121Z</creation></dates><accession>S-EPMC7719607</accession><cross_references><pubmed>32522403</pubmed><doi>10.1016/j.acra.2020.04.012</doi></cross_references></HashMap>